Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kodiak Sciences Inc. KOD
$4.59
-$0.11 (-2.34%)
На 18:01, 12 мая 2023
+614.60%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
247590431.00000000
-
week52high
12.80
-
week52low
4.25
-
Revenue
0
-
P/E TTM
3
-
Beta
1.76910500
-
EPS
-6.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 авг 2022 г. |
| Chardan Capital | Buy | Buy | 10 авг 2022 г. |
| Truist Securities | Buy | Buy | 09 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 09 авг 2022 г. |
| Citigroup | Sell | Neutral | 02 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 ноя 2022 г. |
| Goldman Sachs | Neutral | Neutral | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| EHRLICH JASON | A | 142500 | 142500 | 06 июл 2022 г. |
| BORGESON JOHN A. | A | 142500 | 142500 | 06 июл 2022 г. |
| PERLROTH VICTOR | A | 325000 | 325000 | 06 июл 2022 г. |
| Yang Taiyin | A | 25000 | 25000 | 30 июн 2022 г. |
| PROFUSEK ROBERT | A | 25000 | 25000 | 30 июн 2022 г. |
| Levy Richard S | A | 25000 | 25000 | 30 июн 2022 г. |
| Dahiyat Bassil I | A | 25000 | 25000 | 30 июн 2022 г. |
| Bancroft Charles A | A | 25000 | 25000 | 30 июн 2022 г. |
| BAKER BROS. ADVISORS LP | A | 25000 | 25000 | 30 июн 2022 г. |
| EHRLICH JASON | D | 5625 | 1875 | 17 июн 2022 г. |
Новостная лента
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?
Zacks Investment Research
27 апр 2023 г. в 12:56
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
Zacks Investment Research
04 апр 2023 г. в 14:28
Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why
Zacks Investment Research
03 апр 2023 г. в 12:55
Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.
Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
09 дек 2022 г. в 12:48
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak: Turnaround Strategy Has Shown Life Thus Far
Seeking Alpha
14 ноя 2022 г. в 13:17
Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to have data releases in 2023; GLEAM/GLIMMER/DAYLIGHT/GLOW.